Anti-Inflammatory Drugs Market Size, Share & Industry Analysis, By Drug Class (Anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids), By Application (Autoimmune Inflammatory Diseases (Rheumatoid Arthritis Psoriasis), Respiratory Diseases), By Route of Administration (Oral, Injection, Inhalation, and Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), and Regional Forecast, 2020-2032

The global anti-inflammatory drugs market size was valued at USD 93.88 billion in 2019 and is projected to reach USD 299.95 billion by 2032, exhibiting a CAGR of 9.4% during the forecast period.

Non-steroidal Anti-inflammatory Drugs (NSAIDs) are used as a primary treatment option for pain and inflammation. Many government associations such as the Centers for Disease Control and Prevention advises the use of NSAIDs over opioids. According to a press release of Endo International plc, about 84 million NSAIDs prescriptions are written annually in the U.S. Apart from this, anti-inflammatory biologics is emerging as a shining star in the market. Research on anti-tumor necrosis factor (TNF), interleukins, janus kinase inhibitors, and new product launches are expected to fuel the market. Also, the rising prevalence of autoimmune inflammatory diseases and growing preference for biosimilars are anticipated to augment the market.

MARKET TRENDS

Focus on Developing Biosimilars by Key Pharmaceutical Companies to Augment the Market

Patent expiration of top anti-inflammatory biologics paved its way for the entry of biosimilars in the market. Many manufactures have shifted their focus to the development of biosimilars owing to the increasing demand and easy approval process when compared to a new drug. This has become an important market trend. Biosimilars of adalimumab, infliximab, and etanercept are aiming at attracting high revenue in the market with their reference biologics namely Humira, Ramicade, and Enbrel. A total of 5 biosimilar of AbbVie’s blockbuster drug Humira are approved by the FDA which are likely to belaunched in 2023 in the U.S. While in other regions such as Europe, the adalimumab biosimilar is now commercially available. Moreover, clinical research for developing biosimilars of reference biologics that are about to lose exclusivity in coming years have already been initiated. This is likely to propel the demand for anti-inflammatory therapeutics in the coming years.

MARKET DRIVERS

Potential Pipeline Candidates to Boost Market

Increasing research investments for the development of biologics for the treatment of autoimmune inflammatory diseases has resulted in potential pipeline drugs. The benefits of anti-inflammatory properties of monoclonal antibodies have shifted the focus of pharmaceutical giants towards this area. The companies are focusing on targeting broad inflammatory diseases with anti-tumor necrosis factor (TNF) inhibitors, interleukins, and others. For example,      in December 2019, UCB S.A. announced positive results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis. Apart from this, research and development of NSAIDs and corticosteroids for treating atopic dermatitis, plaque psoriasis, acute pain, and others are projected to drive the anti-inflammatory drugs market in the forecast period.  

Rising Prevalence of Inflammatory Diseases to Aid in Favor of Market

Rising prevalence of inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ulcerative colitis, and others is one of the leading factors driving the anti-inflammatory therapeutics market growth. According to the Centers for Disease Control and Prevention, 78 million adults in the U.S. are estimated to have doctor-diagnosed arthritis by 2040. This is expected to fuel the market during the forecast period. Furthermore, the rising uptake of corticosteroids for the treatment of asthma and chronic obstructive pulmonary disease (COPD) and the rising prevalence of atopic dermatitis are expected to add impetus to market.

MARKET RESTRAINT

Side Effects of NSAIDs are Likely to Hinder Market Growth

Side effects from the Non-Steroids Anti-inflammatory drugs (NSAIDs) such as stomach ulcers, allergic reactions, dizziness, stomach pain, and others are expected to restrict market growth. NSAIDs are among the most commonly prescribed medications as they are effective anti-inflammatory agents. However, NSAIDs-related gastrointestinal complications possess a potential burden on the healthcare system. GI bleeding is the most common reason for a majority of hospital admissions. In the U.S., NSAIDs-related GI complications have become the most common side effect. This is expected to negatively impact the market revenue in the coming years.

SEGMENTATION

By Drug Class Analysis

Anti-inflammatory Biologics Segment to Dominate Market Due to High Drug Sales

On the basis of drug class, the market is segmented into anti-inflammatory biologics, Non-steroidal Anti-inflammatory Drugs (NDAIDs), and corticosteroids. The anti-inflammatory biologics segment accounted for the maximum share in 2019. New product launches, rapid adoption of monoclonal antibodies, and entry of biosimilars are the primary reasons for the growth of this segment. In August 2019, AbbVie announced the launch of RINVOQ, a janus kinase inhibitor for the treatment of rheumatoid arthritis. The NSAIDs segment is anticipated to expand owing to the rising prevalence of inflammatory diseases, expanding applications of NSAIDs, and increasing demand for over-the-counter (OTC) anti-inflammatory therapeutics. Moreover, government recommendations for the use of NSAIDs as the first line of treatment for pain and inflammation are also boosting the demand for NSAIDs. The corticosteroid segment is likely to grow owing to the rising prevalence of COPD, increased research, and potential pipeline candidates.

By Application Analysis

Rising Prevalence of Arthritis to Drive the Autoimmune Inflammatory Diseases Segment

Based on application, the market is segmented into autoimmune inflammatory diseases, respiratory diseases, and others. The autoimmune inflammatory diseases segment can be further bifurcated into rheumatoid arthritis, psoriasis, and others. The autoimmune inflammatory disease segment is estimated to generate maximum revenue in 2019. Primary reasons for the growth of the segment are rising prevalence of rheumatoid arthritis, inflammatory bowel diseases, and psoriasis. The respiratory diseases segment is projected to expand during the forecast period owing to a significant increase in the number of COPD cases and rising uptake of inhaled corticosteroids. The others segment comprises of diseases such as atopic dermatitis, eye diseases, migraine, and others. The rising application of anti-inflammatory drugs in the treatment of various diseases, potential pipeline candidates, and favorable health reimbursement is expected to augment the others segment.

By Route of Administration Analysis

Rising Adoption of Anti-inflammatory biologics to Render Leading Position to the Injection Segment

On the basis of route of administration, the market is segmented into oral, injection, inhalation, and topical. The injection segment is estimated to emerge dominant during the forecast period as almost all the anti-inflammatory biologics are administrated through injections. Focus to launch of oral anti-inflammatory therapeutics, higher sales of Advil, and the increasing availability of generic products are factors contributing to the expansion of the oral segment. Furthermore, the rapid adoption of topical drugs and increasing demand for inhaled corticosteroids are expected to augment the inhalation and topical segmentsbetween2020-2027.

By Distribution Channel Analysis

Hospital Pharmacy to Account for Major Portion of Market

In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2018 owing to the increasing number of prescriptions for anti-inflammatory drugs, favorable health reimbursement, and the rising prevalence of inflammatory diseases. Increased availability of over-the-counter (OTC) drugs, and growing demand for diclofenac, and ibuprofen are likely to foster the retail pharmacy segment. In April 2018, Strides Pharma Inc. received US FDA approval for Ibuprofen OTC capsules which is expected to augment the retail pharmacy segment. The online segment is poised to grow owing to the rising adoption of e-commerce, improving patient convenience, and attractive discounts and coupons on online sales.

REGIONAL ANALYSIS

The anti-inflammatory drugs market in North America stood at USD 41.39 billion in 2019. Increasing demand for anti-inflammatory biologics, government-support for the launch of biosimilars, and significant research investments are the major factors attributable to the expansion of the market in North America. Furthermore, increased sales of Humira, Ramicade, and Enbrel and recommendation from the Centers for Disease Control and Prevention on the use of non-opioid drugs will further help the market to flourish. The demand for anti-inflammatory therapeutics is poised to surge in Europe owing to the active government support for the launch of biosimilars and favorable health reimbursement policies. In October 2018, Amgen announced the launch of Amgevita, a biosimilar of adalimumab in Europe. This is anticipated to foster the market in Europe. Increasing uptake of OTC anti-inflammatory drugs, rising geriatric population, and more preference for generic NSAIDs and corticosteroids are projected to expand the market in Asia Pacific. Factors attributed to the expansion of the markets in Latin America and the Middle East & Africa are rising incidence of rheumatoid arthritis, improving the health infrastructure, and shift of manufacturers focus towards these regions.

KEY INDUSTRY PLAYERS

AbbVie and Johnson & Johnson to Account for Leading Position

In terms of revenue, AbbVie accounted for the maximum portion of the market. This can be attributed to the higher sales of Humira, a multiple indication monoclonal antibody for multiple indications such as rheumatoid arthritis, psoriasis arthritis, ulcerative colitis, and others. In 2019, the company generated US$ 19.2 billion solely from the sale of Humira. Similarly, the high sales of Remicade, Stelara, and Simponi rendered the second position to Johnson and Johnson. However, the introduction of biosimilars for adalimumab and infliximab especially in major markets such as the U.S. and Europe is expected to negatively impact the revenues of the companies.

LIST OF KEY COMPANIES PROFILED:

• AbbVie Inc.


• Merck & Co., Inc.


• Bristol-Myers Squibb Company


• Johnson & Johnson Services, Inc.


• Pfizer Inc.


• Novartis AG


• GlaxoSmithKline plc.


• Eli Lilly and Company


• Amgen Inc.


• Biogen


• Others

KEY INDUSTRY DEVELOPMENTS:

• December 2019 - UCB S.A. announced positive results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis. 


• August 2019 - In August 2019, AbbVie announced the launch of RINVOQ, janus kinase inhibitor for the treatment of rheumatoid arthritis.


• October 2018 - Amgen announced the launch of Amgevita, a biosimilar of adalimumab in Europe.


• April2018 - Strides Pharma Inc. received US FDA approval for Ibuprofen OTC Capsules

REPORT COVERAGE

The anti-inflammatory drugs market report offers a detailed analysis of numerous factors aiding the market both positively and negatively. These include opportunities, growth drivers, threats, key developments, and restraints. In addition to this, the report further helps in analyzing, segmenting, and defining the market based on different segments such as drug class, application, route of administration, and distribution channel. It also provides various key insights such as prevalence of major diseases for key countries, patent snapshot, pipeline analysis, new product launches, key mergers& acquisition, joint ventures, and others.

Report Scope & Segmentation